AbbVie Inc. (NYSE:ABBV) is one of the best performing pharma stocks in 2025. AbbVie Inc. (NYSE:ABBV) was downgraded to Peer ...

“AbbVie is not in discussions with RevMed,” a spokesperson for AbbVie said in a statement to Bloomberg News. The Wall Street ...

AbbVie slides after the company cut guidance, Wolfe Research downgraded the stock and the company pushed back on acquisition reports ...

AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February ...

AbbVie's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Learn more ...

Merck & Co. is in talks to acquire the cancer-focused biotech company Revolution Medicines Inc., according to a report in the ...

AbbVie Inc. said it’s not in talks to acquire the cancer-focused biotech company Revolution Medicines Inc. “AbbVie is not in ...

AbbVie stock fell after denying Revolution Medicines buyout talks. Company also cut 2025 earnings forecast to $9.90-$9.94 per ...

Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China ...

Wolfe upgraded Merck to Outperform from Peer Perform and set a $135 price target, saying the drugmaker is approaching a new ...

AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...

Shares of AbbVie Inc. ABBV slipped 3.98% to $220.18 Monday, on what proved to be an all-around great trading session for the ...